May 11, 2026 08:30AM
Aug 14, 2025 04:05PM
Jul 8, 2025 08:50AM
Jul 7, 2025 08:32AM
Jul 7, 2025 08:30AM
May 15, 2025 04:05PM
Mar 31, 2025 04:05PM Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Nov 14, 2024 04:10PM
Nov 7, 2024 08:32AM
Nov 7, 2024 08:30AM
Aug 13, 2024 04:05PM
Jun 17, 2024 08:31AM
Jun 17, 2024 08:30AM
May 15, 2024 04:15PM Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024 06:55AM
Mar 28, 2024 04:05PM
Mar 11, 2024 04:05PM
Mar 7, 2024 07:05AM
Mar 7, 2024 05:00AM
Dec 11, 2023 08:31AM
Dec 11, 2023 08:30AM Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
Nov 14, 2023 04:10PM
Nov 14, 2023 04:05PM
Nov 2, 2023 09:28AM
Oct 26, 2023 09:03AM
Oct 26, 2023 09:00AM
Aug 16, 2023 08:01AM
Aug 16, 2023 08:00AM Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Aug 14, 2023 04:05PM
Aug 14, 2023 04:01PM
Jun 12, 2023 08:03AM
Jun 12, 2023 08:00AM
May 15, 2023 04:01PM
May 12, 2023 04:05PM
Mar 30, 2023 04:10PM Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
Mar 29, 2023 04:15PM
Dec 19, 2022 08:31AM
Dec 19, 2022 08:30AM
Nov 14, 2022 04:05PM
Nov 14, 2022 04:01PM
Oct 27, 2022 08:04AM
Oct 27, 2022 08:00AM Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macr
Oct 6, 2022 08:30AM
Aug 11, 2022 04:30PM
Aug 11, 2022 04:05PM
Jun 22, 2022 08:00AM
Jun 22, 2022 08:00AM
Jun 22, 2022 08:00AM
May 12, 2022 04:05PM Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 12, 2022 04:05PM

322,680 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All